RAD1 promuove la resistenza all'ossaliplatino nel cancro gastrico rinforzando la difesa antiossidante NRF2 e il segnale di checkpoint DDR.

AIMS: Resistance to oxaliplatin treatment limits therapeutic benefit in gastric cancer (GC) and remains difficult to predict from bulk biomarkers. We aimed to identify oxaliplatin resistance-driving malignant tumor states at single-cell resolution and translate them into clinically tractable predictors. METHODS: Differential expression in oxaliplatin-resistant versus sensitive GC organoids was used to derive a resistance signature, which was evaluated in bulk GC organoid cohorts alongside computational estimate on oxaliplatin sensitivity. Single-cell RNA sequencing (scRNA-seq) was used to localize resistance programs to malignant epithelial states. A multi-constraint integration framework (